Effect of High-intensity Statin Preloading on TIMI Flow in Patients Presenting with ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Overview

Journal Egypt Heart J

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2020 Jul 12

PMID 32651772

Citations 1

Authors

Ahmed Shawky Elserafy

Nabil Mahmoud Farag

Ahmed Ibrahim El Desoky

Khaled Adel Eletriby

Affiliations

Soon will be listed here.

Abstract

Background: Acute ST-elevation myocardial infarction (STEMI) is a major cause of morbidity and mortality worldwide. Primary percutaneous coronary intervention (PCI) has improved the outcomes from STEMI and improved myocardial perfusion. However, there is still room for medical therapy to help perfuse the myocardium. The aim of this study was to assess the impact of high-intensity statins used prior to primary PCI in patients presenting with acute STEMI on myocardial perfusion. The study included 170 patients who presented with acute STEMI to Ain Shams University Hospitals and underwent primary percutaneous coronary intervention (PCI). They were divided into two groups where the first group received high-intensity statins (80 mg of atorvastatin or 20 mg of rosuvastatin) besides guideline-recommended therapy before primary PCI and the second group served as a control group and received guideline-recommended therapy, and high-intensity statins were given as usual after going back to the coronary care unit after primary PCI. Post-interventional thrombolysis in myocardial infarction (TIMI) flow grade and myocardial blush grade (MBG) were recorded, and ST-segment resolution was measured.

Results: The LAD was the culprit vessel for the majority of patients in both groups. In the control group, there were 4 patients with TIMI I flow and MBG I, 13 with TIMI II flow and MBG II, and 68 with TIMI III flow and MBG III. Meanwhile, in the cases group, there was 1 patient with TIMI I flow and MBG I, 3 with TIMI II flow and MBG II, and 81 with TIMI III flow and MBG III. This difference was statistically significant with a P value of 0.010. There were 34 patients in the cases group who showed complete ST-segment resolution (40%) vs. 19 patients (22.4%) in the control group which was statistically significant with a P value of 0.013. In addition, ejection fraction had values of mean ± SD of 45.91 ± 5.49 in the cases group vs. 43.01 ± 8.80 in the control group which was statistically significant with a P value of 0.011.

Conclusion: High-intensity statin loading before primary PCI resulted in improved post-procedural TIMI flow, MBG, complete ST-segment resolution, and ejection fraction.

Citing Articles

Enhanced-Dose Statins for ST-Segment Elevation Myocardial Infarction Patients after Emergency Percutaneous Coronary Intervention.

Chen W, Fan Z, Huang C, Han Z, Liu J Dis Markers. 2022; 2022:2751750.

PMID: 35801005 PMC: 9256331. DOI: 10.1155/2022/2751750.

References

Henriques J, Zijlstra F, van t Hof A, de Boer M, Dambrink J, Gosselink M . Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003; 107(16):2115-9. DOI: 10.1161/01.CIR.0000065221.06430.ED. View

Arca M, Gaspardone A . Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs. 2007; 67 Suppl 1:29-42. DOI: 10.2165/00003495-200767001-00004. View

Briel M, Studer M, Glass T, Bucher H . Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004; 117(8):596-606. DOI: 10.1016/j.amjmed.2004.04.022. View

Hamm C, Bassand J, Agewall S, Bax J, Boersma E, Bueno H . ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment.... Eur Heart J. 2011; 32(23):2999-3054. DOI: 10.1093/eurheartj/ehr236. View

Ray K, Cannon C, McCabe C, Cairns R, Tonkin A, Sacks F . Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46(8):1405-10. DOI: 10.1016/j.jacc.2005.03.077. View

Gibson C, Cannon C, Murphy S, Ryan K, Mesley R, MARBLE S . Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101(2):125-30. DOI: 10.1161/01.cir.101.2.125. View

Ramjane K, Han L, Jin C . The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol. 2009; 13(3):121-8. PMC: 2586408. View

Berwanger O, Santucci E, de Barros E Silva P, de Andrade Jesuino I, Damiani L, Barbosa L . Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018; 319(13):1331-1340. PMC: 5876881. DOI: 10.1001/jama.2018.2444. View

Kim J, Kim J, Choi D, Lee C, Lee S, Ko Y . Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010; 3(3):332-9. DOI: 10.1016/j.jcin.2009.11.021. View

10.

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49(12):1272-8. DOI: 10.1016/j.jacc.2007.02.025. View

11.

Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A . Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009; 54(23):2157-63. DOI: 10.1016/j.jacc.2009.07.005. View

12.

Cuculi F, Lim C, Banning A . Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. Heart. 2010; 96(10):736-40. DOI: 10.1136/hrt.2009.186189. View

13.

Lee K, Woodlief L, Topol E, Weaver W, Betriu A, Col J . Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995; 91(6):1659-68. DOI: 10.1161/01.cir.91.6.1659. View

14.

van t Hof A, Liem A, de Boer M, Zijlstra F . Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997; 350(9078):615-9. DOI: 10.1016/s0140-6736(96)07120-6. View

15.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A . Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009; 54(6):558-65. DOI: 10.1016/j.jacc.2009.05.028. View

16.

Marzilli M . Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2011; 10 Suppl 1:3-9. DOI: 10.2165/1153644-S0-000000000-00000. View